Immunomedics, Inc. Develops Dendritic-Cell Vaccine Technology for Lymphomas and Leukemias

Published: Oct 23, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today! MORRIS PLAINS, N.J., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of U.S. patent no. 8,562,988 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc. (IBC), for "Novel Strategies for Improved Cancer Vaccines."

Help employers find you! Check out all the jobs and post your resume.

Back to news